Monthly Archives: September 2018

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

AUSTIN, Texas & CAMBRIDGE, Mass.--Sept. 6, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More